ZEOX (Zeo ScientifiX) Retained Earnings : $-63.46 Mil (As of Jan. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Zeo ScientifiX's retained earnings for the quarter that ended in Jan. 2025 was $-63.46 Mil.

Zeo ScientifiX's quarterly retained earnings declined from Jul. 2024 ($-60.96 Mil) to Oct. 2024 ($-62.21 Mil) and declined from Oct. 2024 ($-62.21 Mil) to Jan. 2025 ($-63.46 Mil).

Zeo ScientifiX's annual retained earnings declined from Oct. 2022 ($-50.52 Mil) to Oct. 2023 ($-57.51 Mil) and declined from Oct. 2023 ($-57.51 Mil) to Oct. 2024 ($-62.21 Mil).

Zeo ScientifiX Retained Earnings Historical Data

The historical data trend for Zeo ScientifiX's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Retained Earnings Chart

Zeo ScientifiX Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Retained Earnings

Get a 7-Day Free Trial

-28.87

-41.63

-50.52

-57.51

-62.21

Zeo ScientifiX Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Retained Earnings	Get a 7-Day Free Trial															-58.55	-59.95	-60.96	-62.21	-63.46

Zeo ScientifiX Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Zeo ScientifiX (OTCPK:ZEOX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Zeo ScientifiX Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

3321 College Avenue, Suite 246, Davie, FL, USA, 33314

Website

https://www.organicell.com

Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).

Executives

Skycrest Holdings, Llc	10 percent owner	1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider	director, officer: CEO and Director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub	officer: Executive Vice President & CSO	23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich	officer: COO and Acting CEO	4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser	director	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn	director	2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz	director	58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi	director	6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh	director	E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste	director
Ryan C Likes	officer: Chief Operating Officer	1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell	10 percent owner, officer: Chief Financial Officer	77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani	director, officer: Chief Executive Officer	4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140